Skip to main content
Home

Top menu InfoLep

  • About InfoLep
  • News & Events
  • e-learning.infoNTD.org
Home

Main navigation InfoLep

  • Leprosy [5]
    • Global and Regional Leprosy Situation
    • WHO Global Leprosy Strategy
    • ILEP Strategy
    • World Leprosy Day
    • Leprosy journals
  • Key topics [7]
    • Leprosy and COVID-19
    • Diagnostic tests
    • Prevention of leprosy [2]
      • Interventions to reduce transmission: post-exposure prophylaxis (PEP) [3]
        • LPEP Programme
        • PEP++ project
        • PEP4LEP project
      • Interventions to reduce transmission: vaccines
    • Rehabilitation & prevention of disability [2]
      • Preventing leprosy-related disabilities in girls and boys
      • Self-care in leprosy
    • Leprosy Antibiotic Treatment
    • Stigma, discrimination & mental wellbeing [4]
      • World Leprosy Day 2022
      • Gender
      • Mental wellbeing
      • SARI Project
    • Bioarchaeology of leprosy
  • Toolkits [6]
    • Guides on Stigma and Mental Wellbeing [5]
      • Guide 1. What are health-related stigma and mental wellbeing? [8]
        • 1. What is stigma?
        • 2. Why does stigma exist?
        • 3. What are the causes of stigma?
        • 4. Who stigmatises?
        • 5. How does it feel to experience stigma?
        • 6. What are the effects of stigma?
        • 7. Effects of stigma and discrimination on mental wellbeing
        • Annex Guide 1
      • Guide 2. How to reduce the impact of stigma [7]
        • 1. From undetected disease to diagnosis to support
        • 2. Individual-level interventions
        • 3. Group-level interventions
        • 4. Family-level interventions
        • 5. Referral
        • 6. Further reading
        • Annexes Guide 2
      • Guide 3. How to reduce sources of stigma [6]
        • 1. Background to the design of a stigma-reduction intervention
        • 2. Identifying the sources of stigma
        • 3. Targeting an intervention
        • 4. Inclusion of affected persons and champions in interventions
        • 5. Interventions by source type
        • Annexes Guide 3
      • Guide 4. How to assess health-related stigma and mental wellbeing [9]
        • 1. What is the purpose of the assessment?
        • 2. What approach would best fit your purpose and context?
        • 3. Quantitative assessment methods
        • 4. Qualitative assessment methods
        • 5. Assessments using mixed methods
        • 6. Developing qualitative methods from scratch
        • 7. How do you conduct a stigma assessment?
        • 8. How to interpret and report your findings
        • Annexes Guide 4
      • Glossary
    • NTD Morbidity and Disability Toolkit [15]
      • CHIEF
      • Clinical Profile
      • EMIC affected persons
      • EMIC-CS Community Stigma
      • Participation Scale
      • Patient Health Questionnaire (PHQ-9)
      • 5-Question Stigma Indicators
      • Salsa Scale
      • SARI Stigma Scale
      • SDS Social Distance Scale
      • SRQ Self-reporting Questionnaire
      • Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS)
      • WGQ Washington Group Questions
      • WHODAS
      • WHOQOL-BREF
    • Perception Study Toolkit (PST)
    • Zero Leprosy Toolkit
    • CBM's Community Mental Health Good Practice Guides
    • GPZL & Infolep Factsheets
  • Online courses
  • Ocular DB

Top menu InfoLep

  • About InfoLep
  • News & Events
  • e-learning.infoNTD.org
Visit our e-learning platform
Search resources Search in Practical Materials, Publications, Organizations, Online Course and more
Publication

Highlights of the Pre Congress Workshop No. 7 January 29th and 30th 2008; International Leprosy Congress, 2008 Hyderabad, India

Sundar Rao PSS, Chandna R. Lepra. Leprosy Review. 2008; 79 (2) : 223-229.
Download PDF
Publication

John Leslie Turk, MD, DSc, FRCP, FRCS, FRCPath (1930–2006)

Allen I. Lepra. Leprosy Review. 2007; 78 (4) : 409-413.
Download PDF
Publication

INDEPENDENT EVALUATION OF GAEL

Daumerie D. Lepra. Leprosy Review. 2004; 75 (4) : 407-408.
Download PDF
Publication

A STRATEGY TO IMPROVE THE ML FLOW TEST FOR DETECTION OF ANTI-PHENOLIC GLYCOLIPID-1 ANTIBODIES: REPLY

Oskam L, Bührer-Sékula S. Lepra. Leprosy Review. 2004; 75 (2) : 194-195.
Download PDF
Publication

REPLY TO LETTER BY SUBMITTED BY DUTCH NEUROPATHIC FOOT SOCIETY

Wim Brandsma J, Macdonald M. Lepra. Leprosy Review. 2003; 74 (1) : 86-86.
Download PDF
Publication

SOCIO-ECONOMIC REHABILITATION IN LEPROSY—AN EXAMPLE

Joseph Kawuma H. Lepra. Leprosy Review. 2003; 74 (1) : 83-83.
Download PDF
Publication

Adverse effects of polychemotherapy for leprosy in 13 years of follow-up at a university hospital.

Tortelly V, Daxbacher EL, Brotas AM, et al. Anais brasileiros de dermatologia. 2021;
Download PDF
Publication

Hepatitis B Virus Infection Among Leprosy Patients: A Case for Polymorphisms Compromising Activation of the Lectin Pathway and Complement Receptors.

Boldt A, Oliveira-Toré C, Kretzschmar GC, et al. Frontiers in immunology. 2020;
Download PDF
Publication

Magnitude and temporal trends of leprosy relapse in the state of Ceará, Brazil in the period 2001-2018.

Nzundu Boigny R, Florêncio CMGD, Cavalcante K, et al. Revista da Sociedade Brasileira de Medicina Tropical. 2021;
Download PDF
Publication

Protecting the neglected from disease: the role of gender, health equity and human rights in the fight against neglected tropical diseases

de Rijk S, Klemperer K, Depierreux D, et al. Polygeia TDR. 2021;
Download PDF

Pagination

  • Previous page ‹‹
  • Page 295
  • Next page ››
Subscribe to Full text online

Quick links

  • Leprosy
  • Key topics
  • Toolbox
  • Publications

Support

  • Contact
  • Privacy statement
  • Contact
  • FAQ

Contact us

info@infolep.org

(+31) 20 595 0500

     

Stay up to date with the latest publications and news related to leprosy.

Subscribe to newsletter

Related websites:

© 2025 InfoNTD